Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News EOM Pharmaceutical Holdings Inc IMUC

Healthcare Biotechnology
EOM Pharmaceutical Holdings, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing novel drugs for patients suffering from debilitating and deadly diseases, including infectious diseases; autoimmune diseases including rheumatoid arthritis; and cachexia associated with acquired immune deficiency syndrome (AIDS) and cancer. It has two pipeline assets in their... see more

Recent & Breaking News (PINL:IMUC)

ImmunoCellular Therapeutics Announces Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update

PR Newswire March 9, 2017

ImmunoCellular Therapeutics to Report Fourth Quarter and Full Year 2016 Financial Results on March 9, 2017

PR Newswire March 6, 2017

ImmunoCellular Therapeutics Provides Update on ICT-107 Phase 3 Glioblastoma Trial and Announces Advances in Stem-to-T-Cell Research Program

PR Newswire March 6, 2017

15 Biggest Mid-Day Losers For Wednesday

Benzinga.com  January 11, 2017

ImmunoCellular Therapeutics Announces Management Changes

PR Newswire December 14, 2016

Research Reports Initiation on Biotech Stocks -- CorMedix, Trevena, Regulus Therapeutics, and ImmunoCellular Therapeutics

PR Newswire December 13, 2016

ImmunoCellular Therapeutics Reports Updated Immune Monitoring Data from ICT-107 Phase 2 Trial in Newly Diagnosed Glioblastoma at the Society for Neuro-Oncology Annual Meeting 2016

PR Newswire November 21, 2016

ImmunoCellular Therapeutics Announces One-for-Forty Reverse Stock Split

PR Newswire November 16, 2016

ImmunoCellular Therapeutics Announces Third Quarter 2016 Financial Results and Provides Research and Development Update

PR Newswire November 10, 2016

ImmunoCellular Therapeutics to Report Third Quarter 2016 Financial Results on November 10, 2016

PR Newswire November 2, 2016

Cryoport and Database Integrations Launch Integrated Solution to Manage Patient and Manufacturer Schedules at Every Stage of the Clinical Trial Logistics Process

PR Newswire September 22, 2016

ImmunoCellular Therapeutics Announces Second Quarter 2016 Financial Results

PR Newswire August 22, 2016

Earnings Scheduled For August 22, 2016

Benzinga.com  August 22, 2016

ImmunoCellular Therapeutics to Report Second Quarter 2016 Financial Results on August 22, 2016

PR Newswire August 17, 2016

ImmunoCellular Therapeutics Treats First Patient in ICT-107 Phase 3 Registrational Trial in Newly Diagnosed Glioblastoma

PR Newswire June 7, 2016

ImmunoCellular Therapeutics to Present at Marcum MicroCap Conference on June 2, 2016

PR Newswire May 23, 2016

BioLife Solutions and MNX Global Logistics Partner to Support ImmunoCellular Therapeutics with Cold Chain Logistics in ICT-107 Phase 3 Clinical Trial in Glioblastoma

PR Newswire May 19, 2016

ImmunoCellular Therapeutics Announces First Quarter 2016 Financial Results

PR Newswire May 12, 2016

ImmunoCellular Therapeutics Receives Regulatory Approval in Canada, the UK and the Netherlands to Initiate ICT-107 Phase 3 Trial in Newly Diagnosed Glioblastoma

PR Newswire May 6, 2016

ImmunoCellular Therapeutics to Report First Quarter 2016 Financial Results on May 12, 2016

PR Newswire May 4, 2016